We are live on ! Find out more
LRMR icon

Larimar Therapeutics

116 hedge funds and large institutions have $245M invested in Larimar Therapeutics in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 32 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

432% more call options, than puts

Call options by funds: $2.13M | Put options by funds: $400K

38% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 32

1.4% less ownership

Funds ownership: 100.81%99.41% (-1.4%)

6% less funds holding

Funds holding: 123116 (-7)

19% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 27

42% less capital invested

Capital invested by funds: $421M → $245M (-$176M)

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
116
Holders Change
-7
Holders Change %
-5.69%
% of All Funds
1.53%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
22
Increased
44
Reduced
32
Closed
27
Calls
$2.13M
Puts
$400K
Net Calls
+$1.73M
Net Calls Change
-$243K
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$82.2M
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$24.9M +$5.79M +876,431 +16%
RCM
3
RA Capital Management
Massachusetts
$23.4M
BOCH
4
Blue Owl Capital Holdings
New York
$18M +$3.21M +486,211 +12%
Goldman Sachs
5
Goldman Sachs
New York
$16.1M -$642K -97,263 -2%
BlackRock
6
BlackRock
New York
$12.6M +$1.93M +292,952 +10%
Vanguard Group
7
Vanguard Group
Pennsylvania
$8.49M -$689K -104,324 -5%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$8.13M +$2.63M +399,123 +23%
DCM
9
Driehaus Capital Management
Illinois
$4.91M -$60.9K -9,232 -0.7%
Verition Fund Management
10
Verition Fund Management
Connecticut
$4.02M -$819K -124,002 -11%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$3.81M +$1.81M +273,920 +39%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.43M -$98K -14,848 -2%
State Street
13
State Street
Massachusetts
$3.26M -$471K -71,427 -8%
MP
14
Mangrove Partners
Connecticut
$2.98M -$565K -85,582 -10%
FAM
15
Fred Alger Management
New York
$2.85M -$324K -49,035 -6%
WP
16
Woodline Partners
California
$2.41M -$4.11M -621,869 -50%
Renaissance Technologies
17
Renaissance Technologies
New York
$1.99M +$1.05M +159,700 +45%
ACM
18
Altium Capital Management
New York
$1.95M -$1.24M -188,000 -27%
SFM
19
Sphera Funds Management
Israel
$1.76M +$271K +41,126 +10%
Northern Trust
20
Northern Trust
Illinois
$1.46M +$198K +29,924 +9%
DCM
21
DAFNA Capital Management
California
$1.44M -$811K -122,840 -25%
Millennium Management
22
Millennium Management
New York
$987K -$3.36M -508,912 -67%
CSS
23
Cubist Systematic Strategies
Connecticut
$905K +$1.14M +172,131 +279%
Assenagon Asset Management
24
Assenagon Asset Management
Luxembourg
$851K -$42.8K -6,488 -3%
UOC
25
UBS O'Connor
Illinois
$730K -$94K -14,240 -7%

LRMR Hedge Fund Activity: Q4 2024 in Review

116 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2024, worth a combined $245M — down 42% from $421M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of LRMR and 22 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 44 added.

The largest buyer was Janus Henderson Group, adding an estimated $5.79M. The largest seller was Woodline Partners, cutting an estimated $4.11M.

  • 116 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2024, down from 123 in Q3 2024.
  • Funds reported $245M of Larimar Therapeutics stock for Q4 2024, down 42% quarter-over-quarter.
  • 22 funds opened new Larimar Therapeutics positions in Q4 2024 and 27 closed out, a net change of -5 holders.
  • The largest Larimar Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $5.79M added.
  • The largest Larimar Therapeutics seller in Q4 2024 was Woodline Partners, an estimated $4.11M sold.

Based on aggregated 13F filings for Q4 2024.